SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and...
-
Upload
corey-crawford -
Category
Documents
-
view
223 -
download
2
Transcript of SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and...
![Page 1: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/1.jpg)
SoS
Clinical Trial Commentary
Dr Eric TopolProvost and Chief Academic OfficerChairman and Professor, Department of CardiologyCleveland Clinic
Dr Robert CaliffProfessor of Cardiology Associate Vice Chancellor for Clinical Research at Duke University
![Page 2: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/2.jpg)
Study design
International study: 11 European countries and Canada
Trial design: Comparing CABG and stent-assisted
angioplasty in patients with multivessel disease.
Primary end point:need for additional revascularizations
Secondary end point: composite of death or nonfatal Q-wave
MI, and all-cause mortality.
SoS
![Page 3: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/3.jpg)
Mortality rates: SoS
All deaths reported* 1.2%
CABG(n=500)
Mortality
SoS
All deaths at 1 year
4.1%
2.5% 0.8%
PCI(n=488)
* As of presentation at ACC 2001; p value = 0.007
![Page 4: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/4.jpg)
An unexpected result
Some explanations for the finding:
CABG was remarkably well done
8 cancer deaths in the PCI arm skewed the results
Repeat TVR was less surprising:20.3% for PCI5.8% for CABG
SoS
![Page 5: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/5.jpg)
Mortality rate: ARTS
All deaths* 2.8%
CABG(n=605)
Mortality at 1 year
SoS
2.5%
PCI(n=600)
*p value = n/s
Serruys et al. N Engl J Med 2001; 344: 1117-24.
![Page 6: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/6.jpg)
Response to the study
SoS has an imbalance in mortality risk favoring bypass surgery.
The interventional cardiology community largely ignored SoS, as if they dismissed it because they didn’t like the data.
Topol
SoS
![Page 7: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/7.jpg)
Confusing results
This reinforces my belief that the more complicated the anatomy, the better CABG is than PCI.
Nothing has convinced me that stenting will fix that for PCI.
Stenting does reduce the number of repeat revascularizations.
Califf
SoS
![Page 8: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/8.jpg)
“I really do think that ultimately for bad multi-vessel disease it boils down to a matter of plumbing -- how many open conduits do you have? And it’s going to be pretty hard to beat surgery in this regard.”
Dr Robert CaliffProfessor of Cardiology Associate Vice Chancellor for Clinical Research at Duke University
SoS
Plumbing
![Page 9: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/9.jpg)
Quality of surgery
The excess in cancer deaths is a fluke, but the cardiovascular deaths still show the same trend.
Surgical quality is critical, especially in clinical trials.
The quality of the surgery isn’t consistent across the globe.
Califf
SoS
![Page 10: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/10.jpg)
CABG mortality
But this rate of first-operation mortality for bypass, in the peri-1%, that's not so unusual these days, is it?
Topol
For patients who qualify for PCI, it isn’t that much of a surprise. I'll bet if you look at the Cleveland Clinic, at patients like this, it's considerably less than 1%. So I don't think the trial is totally a fluke.
Califf
SoS
![Page 11: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/11.jpg)
Small diabetic population
So few patients with insulin-dependent diabetes makes the results even more striking.
Califf
There wasn't much in the way of IIb/IIIa inhibitor use in the trial, which might have neutralized some of the stent liability in diabetics, but that wasn't the case.
Topol
SoS
![Page 12: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/12.jpg)
RITA trial
RITA trialmortality at 2.5 year follow-up: 3.6% for CABG 3.1% for PTCA
RITA was discounted by the interventional cardiology community because they didn't like the data.
SoS was rigorously done and the cancer deaths don’t explain it away.
Topol
SoS
![Page 13: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/13.jpg)
Pump head
SoS included a prospective assessment on congnitive function.
Some have discounted surgery's success in the trial because of “pump head.” (The patients are alive but their brain isn’t working.)
Topol
SoS
![Page 14: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/14.jpg)
Percentage of patients suffering decline in cognitive function by >20% post-CABG compared to pre-CABG baseline
At 5 yearsAt discharge
Newman et al. N Engl J Med 2001; 344: 395-402.
53%
At 6 weeks
36% 24% 42%
At 6 months
SoS
Cognitive decline with CABG
![Page 15: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/15.jpg)
Cognitive decline in SoS
I would be surprised if cognitive decline is a factor.
Patients who are at highest risk for "pump head" tend to be the worst candidates for PCI: horrific atherosclerosis LV dysfunction elderly
Califf
SoS
![Page 16: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/16.jpg)
MASS, ARTS, SoS
Three trials have not settled the question:ARTS, SoS, MASS
Just stenting has not achieved parity in outcomes.
The disparity in mortality remains troubling.
Topol
SoS
![Page 17: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/17.jpg)
Putting it together
The studies need to be looked at side by side, in an overview as well as separately.
Unfortunately, in this field, it hasn't been done as effectively as it has been for other medical therapies (eg BARI).
To this day, there still is not a by-patient systematic overview of bypass surgery vs angioplasty.
Califf
SoS
![Page 18: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/18.jpg)
Best of both worlds. SoS
“It seems to me that ultimately the two procedures need to be combined. That there are probably some vessels within a patient that would do just as well with a stent, and there are others that perhaps are ideal for off-pump bypass. And that somehow combining those two, you ought to be able to get the best of both worlds.”
Dr Robert CaliffProfessor of Cardiology Associate Vice Chancellor for Clinical Research at Duke University
![Page 19: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/19.jpg)
Hybrid procedure.
A hybrid procedure will be increasingly popular.
Stenting will continue to get better, with coated stents and with better adjunctive medications.
Off-pump surgery, and ultimately even percutaneous bypass might be possible.
Topol
SoS
![Page 20: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/20.jpg)
Dichotomization
We only have three trials so far - it would be hard to say that bypass surgery is the treatment of choice for multivessel disease.
I don’t think the interventional cardiology community is going to succumb just yet
Topol
There is some dichotomization due to trade-unionism, which I hope we can get over.
Califf
SoS
![Page 21: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/21.jpg)
“In the best of all worlds it would be nice to have an independent opinion. Ideally, it would be nice if you had this really proficient angiographer who didn't necessarily do interventions, or would be able to review a cath without a bias, to be the honest broker to make decisions. But we don't have that.”
Dr Eric TopolProvost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic
SoS
Surgery or stenting, who decides?
![Page 22: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/22.jpg)
Enough for everyone
Operator experience is a factor, some of the most experienced operators tend to be very aggressive.
Topol
With the aging population, there should be enough business for everyone. There should be a more rational system to have the right patient get the right procedure.
Califf
SoS
![Page 23: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/23.jpg)
SoS trial review
Dr Robert Califf
One thumb up
"We need to see the final data; particularly the quality-of-life data."
SoS
![Page 24: SoS Clinical Trial Commentary Dr Eric Topol Provost and Chief Academic Officer Chairman and Professor, Department of Cardiology Cleveland Clinic Dr Robert.](https://reader035.fdocuments.us/reader035/viewer/2022062321/56649dea5503460f94ae4fc9/html5/thumbnails/24.jpg)
SoS trial review
Dr Eric Topol
Two thumbs up
“Well done, well-presented, and just the kind of trial we need.”
SoS